Nobutaka Hattori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3369635/publications.pdf

Version: 2024-02-01

215 papers

19,003 citations

49 h-index

47409

133 g-index

220 all docs 220 docs citations

times ranked

220

20368 citing authors

#	Article	IF	CITATIONS
1	Multiple sclerosis plaques may undergo continuous myelin degradation: a cross-sectional study with myelin and axon-related quantitative magnetic resonance imaging metrics. Neuroradiology, 2022, 64, 465-471.	1.1	4
2	Comorbid alpha synucleinopathies in idiopathic normal pressure hydrocephalus. Journal of Neurology, 2022, 269, 2022-2029.	1.8	7
3	Genotype-phenotype correlation of Parkinson's disease with PRKN variants. Neurobiology of Aging, 2022, 114, 117-128.	1.5	13
4	Efficacy of BCG vaccine in animal models of neurological disorders. Vaccine, 2022, 40, 432-436.	1.7	6
5	Neuroimaging Pearls from the <scp>MDS</scp> Congress Video Challenge. Part 2: Acquired Disorders. Movement Disorders Clinical Practice, 2022, 9, 311-325.	0.8	2
6	Effects of rasagiline on Parkinson's Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson's disease: A post-hoc analysis of clinical trials in Japan. PLoS ONE, 2022, 17, e0262796.	1.1	1
7	Current Status of Telemedicine for Parkinson's Disease in Japan: A Single-Center Cross-Sectional Questionnaire Survey. Journal of Movement Disorders, 2022, 15, 58-61.	0.7	9
8	White matter microstructures in Parkinson's disease with and without impulse control behaviors. Annals of Clinical and Translational Neurology, 2022, , .	1.7	6
9	Deep Brain Stimulation for a Patient with Familial Parkinson's Disease Harboring <scp><i>CHCHD2</i></scp> p. <scp>T61I</scp> . Movement Disorders Clinical Practice, 2022, 9, 407-409.	0.8	2
10	Multimodal magnetic resonance imaging quantification of gray matter alterations in relapsingâ€remitting multiple sclerosis and neuromyelitis optica spectrum disorder. Journal of Neuroscience Research, 2022, 100, 1395-1412.	1.3	3
11	Size-reweighted cascaded fully convolutional network for substantia nigra segmentation from T2 MRI. , 2022, , .		O
12	Rigid real-time prospective motion-corrected three-dimensional multiparametric mapping of the human brain. Neurolmage, 2022, 255, 119176.	2.1	5
13	Network Centrality Analysis Characterizes Brain Activity during Response Inhibition in Right Ventral Inferior Frontal Cortex. Juntendo Medical Journal, 2022, 68, 208-211.	0.1	3
14	Parkin Deficiency Impairs Mitochondrial <scp>DNA</scp> Dynamics and Propagates Inflammation. Movement Disorders, 2022, 37, 1405-1415.	2.2	28
15	Extremely low-frequency pulses of faint magnetic field induce mitophagy to rejuvenate mitochondria. Communications Biology, 2022, 5, 453.	2.0	9
16	Prospective Five-Year Follow-Up of Patients with Schizophrenia Suspected with Parkinson's Disease. Parkinson's Disease, 2022, 2022, 1-8.	0.6	0
17	Impaired mitochondrial accumulation and Lewy pathology in neuron-specific FBXO7-deficient mice. Molecular Brain, 2022, 15, .	1.3	6
18	Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson's Disease: Online-Based Delphi Survey. Parkinson's Disease, 2022, 2022, 1-9.	0.6	0

#	Article	IF	CITATIONS
19	The identified clinical features of Parkinson's disease in homo-, heterozygous and digenic variants of PINK1. Neurobiology of Aging, 2021, 97, 146.e1-146.e13.	1.5	14
20	PLA2G6 variants associated with the number of affected alleles in Parkinson's disease in Japan. Neurobiology of Aging, 2021, 97, 147.e1-147.e9.	1.5	14
21	Cerebral artery dissection secondary to antiphospholipid syndrome: A report of two cases and a literature review. Lupus, 2021, 30, 118-124.	0.8	6
22	Analysis for Stroke Etiology in Duplicated/Accessory MCA-Related Cerebral Infarction: Two Case Report and Brief Literature Review. Diagnostics, 2021, 11, 205.	1.3	2
23	New modalities and directions for dystonia care. Journal of Neural Transmission, 2021, 128, 559-565.	1.4	6
24	Measurement of GCase Activity in Cultured Cells. Methods in Molecular Biology, 2021, 2322, 47-52.	0.4	0
25	Novel Variants in the CLCN1, RYR2, and DCTN1 Found in Elderly Japanese Dementia Patients: A Case Series. Geriatrics (Switzerland), 2021, 6, 14.	0.6	1
26	Learning Deficits Accompanied by Microglial Proliferation After the Long-Term Post-Injection of Alzheimer's Disease Brain Extract in Mouse Brains. Journal of Alzheimer's Disease, 2021, 79, 1701-1711.	1.2	3
27	A mucosal immune response induced by oral administration of heat-killed Mycobacterium avium subsp. paratuberculosis exacerbates EAE. Journal of Neuroimmunology, 2021, 352, 577477.	1.1	10
28	Abstract P349: Neuroprotective Effects of L-Carnitine on Vascular Dementia in Hemodialysis Patients. Stroke, 2021, 52, .	1.0	0
29	Strain-specific clearance of seed-dependent tau aggregation by lithium-induced autophagy. Biochemical and Biophysical Research Communications, 2021, 543, 65-71.	1.0	6
30	Clinical manifestations of Parkinson's disease harboring VPS35 retromer complex component p.D620N with long-term follow-up. Parkinsonism and Related Disorders, 2021, 84, 139-143.	1.1	12
31	Possible Neuroprotective Effects of l-Carnitine on White-Matter Microstructural Damage and Cognitive Decline in Hemodialysis Patients. Nutrients, 2021, 13, 1292.	1.7	4
32	A Novel LRRK2 Variant p.G2294R in the WD40 Domain Identified in Familial Parkinson's Disease Affects LRRK2 Protein Levels. International Journal of Molecular Sciences, 2021, 22, 3708.	1.8	7
33	Differentiation between multiple sclerosis and neuromyelitis optica spectrum disorders by multiparametric quantitative MRI using convolutional neural network. Journal of Clinical Neuroscience, 2021, 87, 55-58.	0.8	8
34	Cerebrovascular diseases in two patients with entire NSD1 deletion. Human Genome Variation, 2021, 8, 20.	0.4	2
35	Genetic analysis of ATP10B for Parkinson's disease in Japan. Parkinsonism and Related Disorders, 2021, 88, 10-12.	1.1	5
36	Case Report: Chronic Adaptive Deep Brain Stimulation Personalizing Therapy Based on Parkinsonian State. Frontiers in Human Neuroscience, 2021, 15, 702961.	1.0	19

#	Article	IF	Citations
37	Potential of PINK1 and PARKIN Proteins as Biomarkers for Active Multiple Sclerosis: A Japanese Cohort Study. Frontiers in Immunology, 2021, 12, 681386.	2.2	12
38	Diffusion MRI Captures White Matter Microstructure Alterations in PRKN Disease. Journal of Parkinson's Disease, 2021, 11, 1221-1235.	1.5	1
39	UQCRC1 engages cytochrome c for neuronal apoptotic cell death. Cell Reports, 2021, 36, 109729.	2.9	13
40	White matter alterations in Parkinson's disease with levodopa-induced dyskinesia. Parkinsonism and Related Disorders, 2021, 90, 8-14.	1.1	9
41	Parallel cognitive processing streams in human prefrontal cortex: Parsing areal-level brain network for response inhibition. Cell Reports, 2021, 36, 109732.	2.9	15
42	3D Quantitative Synthetic MRI in the Evaluation of Multiple Sclerosis Lesions. American Journal of Neuroradiology, 2021, 42, 471-478.	1.2	16
43	iPSC-based Drug Screening for PARK9, a Familial Parkinson's Disease with Impaired Autophagy. Juntendo Medical Journal, 2021, 67, 450-450.	0.1	0
44	White matter and nigral alterations in multiple system atrophy-parkinsonian type. Npj Parkinson's Disease, 2021, 7, 96.	2.5	10
45	Accelerated Isotropic Multiparametric Imaging by High Spatial Resolution 3D-QALAS With Compressed Sensing. Investigative Radiology, 2021, 56, 292-300.	3.5	23
46	Varicella-zoster virus encephalitis resembling herpes simplex virus encephalitis. BMJ Case Reports, 2021, 14, e247602.	0.2	0
47	MR Biomarkers of Degenerative Brain Disorders Derived From Diffusion Imaging. Journal of Magnetic Resonance Imaging, 2020, 52, 1620-1636.	1.9	75
48	Freezing of gait in Parkinson's disease may share the mechanisms of dystonia. Neurological Sciences, 2020, 41, 1285-1286.	0.9	5
49	Analysis of Clinical Symptoms and Brain MRI of Heat Stroke: 2 Case Reports and a Literature Review. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104511.	0.7	14
50	Astrocytes Protect Human Dopaminergic Neurons from \hat{l}_{\pm} -Synuclein Accumulation and Propagation. Journal of Neuroscience, 2020, 40, 8618-8628.	1.7	57
51	Functional Organization for Response Inhibition in the Right Inferior Frontal Cortex of Individual Human Brains. Cerebral Cortex, 2020, 30, 6325-6335.	1.6	28
52	Motor/Nonmotor Symptoms and Progression in Patients with Parkinson's Disease: Prevalence and Risks in a Longitudinal Study. Parkinson's Disease, 2020, 2020, 1-13.	0.6	8
53	Asparagine residue 368 is involved in Alzheimer's disease tau strain–specific aggregation. Journal of Biological Chemistry, 2020, 295, 13996-14014.	1.6	10
54	Mitochondrial <i>UQCRC1</i> mutations cause autosomal dominant parkinsonism with polyneuropathy. Brain, 2020, 143, 3352-3373.	3.7	37

#	Article	IF	Citations
55	Immunotoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities. Toxins, 2020, 12, 658.	1.5	14
56	Pleiotropic Effects of Exosomes as a Therapy for Stroke Recovery. International Journal of Molecular Sciences, 2020, 21, 6894.	1.8	16
57	Gene expression profiling in neuronal cells identifies a different type of transcriptome modulated by NF-Y. Scientific Reports, 2020, 10, 21714.	1.6	4
58	Elsevier/NSR Symposium: The 20th Anniversary of Parkin Discovery-To the Past, the Present, and the Future Neuroscience Research, 2020, 159, 1-2.	1.0	0
59	Lipids: Key Players That Modulate α-Synuclein Toxicity and Neurodegeneration in Parkinson's Disease. International Journal of Molecular Sciences, 2020, 21, 3301.	1.8	36
60	Clinical characterization of patients with leucine-rich repeat kinase 2 genetic variants in Japan. Journal of Human Genetics, 2020, 65, 771-781.	1.1	15
61	A novel rare variant of LRRK2 associated with familial Parkinson's disease: p.R1501W. Parkinsonism and Related Disorders, 2020, 76, 46-48.	1.1	3
62	Network Centrality Reveals Dissociable Brain Activity during Response Inhibition in Human Right Ventral Part of Inferior Frontal Cortex. Neuroscience, 2020, 433, 163-173.	1.1	16
63	FACS-array–based cell purification yields a specific transcriptome of striatal medium spiny neurons in a murine Huntington disease model. Journal of Biological Chemistry, 2020, 295, 9768-9785.	1.6	9
64	Neurocognitive and psychiatric disordersâ€related axonal degeneration in Parkinson's disease. Journal of Neuroscience Research, 2020, 98, 936-949.	1.3	15
65	Young age and severity of motor function are risk factors for psychosis after subthalamic nucleus deep brain stimulation for Parkinson's disease. Psychiatry and Clinical Neurosciences, 2020, 74, 328-329.	1.0	0
66	Myelin Measurement Using Quantitative Magnetic Resonance Imaging: A Correlation Study Comparing Various Imaging Techniques in Patients with Multiple Sclerosis. Cells, 2020, 9, 393.	1.8	28
67	Nonmercaptalbumin as an oxidative stress marker in Parkinson's and PARK2 disease. Annals of Clinical and Translational Neurology, 2020, 7, 307-317.	1.7	22
68	Characteristics of Clinical Symptoms, Cerebral Images and Stroke Etiology in Vertebro-Basilar Artery Fenestration-Related Infarction. Brain Sciences, 2020, 10, 243.	1.1	9
69	The absence of orthostatic heart rate increase is associated with cognitive impairment in Parkinson's disease. PLoS ONE, 2020, 15, e0240491.	1.1	10
70	Reply: ARSA gene variants and Parkinson's disease. Brain, 2020, 143, e48-e48.	3.7	0
71	Title is missing!. , 2020, 15, e0240491.		0
72	Title is missing!. , 2020, 15, e0240491.		0

#	Article	lF	Citations
73	Title is missing!. , 2020, 15, e0240491.		O
74	Title is missing!. , 2020, 15, e0240491.		0
75	Free-Water Imaging in White and Gray Matter in Parkinson's Disease. Cells, 2019, 8, 839.	1.8	44
76	Convolutional neural network-based segmentation can help in assessing the substantia nigra in neuromelanin MRI. Neuroradiology, 2019, 61, 1387-1395.	1.1	36
77	More subjects are required for ventrolateral than dorsolateral prefrontal TMS because of intolerability and potential drop-out. PLoS ONE, 2019, 14, e0217826.	1.1	6
78	Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone. Brain, 2019, 142, 2845-2859.	3.7	44
79	Mutation analysis of LRP10 in Japanese patients with familial Parkinson's disease, progressive supranuclear palsy, and frontotemporal dementia. Neurobiology of Aging, 2019, 84, 235.e11-235.e16.	1.5	10
80	Omega-3 Polyunsaturated Fatty Acids and Stroke Burden. International Journal of Molecular Sciences, 2019, 20, 5549.	1.8	14
81	MRI-based visualization of rTMS-induced cortical plasticity in the primary motor cortex. PLoS ONE, 2019, 14, e0224175.	1.1	16
82	White Matter Abnormalities in Multiple Sclerosis Evaluated by Quantitative Synthetic MRI, Diffusion Tensor Imaging, and Neurite Orientation Dispersion and Density Imaging. American Journal of Neuroradiology, 2019, 40, 1642-1648.	1.2	33
83	Parkinson's disease-associated <i>iPLA2-VIA/</i> PLA2G6 regulates neuronal functions and α-synuclein stability through membrane remodeling. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20689-20699.	3.3	67
84	An Essential Role of the Intraparietal Sulcus in Response Inhibition Predicted by Parcellation-Based Network. Journal of Neuroscience, 2019, 39, 2509-2521.	1.7	59
85	Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson's disease. Journal of Neural Transmission, 2019, 126, 299-308.	1.4	8
86	Improving the Quality of Synthetic FLAIR Images with Deep Learning Using a Conditional Generative Adversarial Network for Pixel-by-Pixel Image Translation. American Journal of Neuroradiology, 2019, 40, 224-230.	1.2	59
87	Adjuvant and antigenic properties of Mycobacterium avium subsp. paratuberculosis on experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2019, 330, 174-177.	1.1	14
88	Loss of nuclear REST/NRSF in aged-dopaminergic neurons in Parkinson's disease patients. Neuroscience Letters, 2019, 699, 59-63.	1.0	38
89	Brain tissue and myelin volumetric analysis in multiple sclerosis at 3T MRI with various in-plane resolutions using synthetic MRI. Neuroradiology, 2019, 61, 1219-1227.	1.1	21
90	Deep brain stimulation shows high efficacy in two patients with GCH1 variants. Parkinsonism and Related Disorders, 2019, 65, 277-278.	1.1	6

#	Article	IF	CITATIONS
91	Gray Matter Alterations in Early and Late Relapsing-Remitting Multiple Sclerosis Evaluated with Synthetic Quantitative Magnetic Resonance Imaging. Scientific Reports, 2019, 9, 8147.	1.6	16
92	Iron Supply via NCOA4-Mediated Ferritin Degradation Maintains Mitochondrial Functions. Molecular and Cellular Biology, 2019, 39, .	1.1	45
93	Increased Lysosomal Exocytosis Induced by Lysosomal Ca ²⁺ Channel Agonists Protects Human Dopaminergic Neurons from α-Synuclein Toxicity. Journal of Neuroscience, 2019, 39, 5760-5772.	1.7	93
94	Specific mechanisms of subarachnoid hemorrhage accompanied by ischemic stroke in essential thrombocythemia: two case reports and a literature review. Journal of Neurology, 2019, 266, 1869-1878.	1.8	13
95	Parkinsonism Relating to Intoxication with Glyphosate. Internal Medicine, 2019, 58, 1935-1938.	0.3	27
96	Metabolomicsâ€based identification of metabolic alterations in PARK2. Annals of Clinical and Translational Neurology, 2019, 6, 525-536.	1.7	44
97	Tau aggregation and seeding analyses of two novel MAPT variants found in patients with motor neuron disease and progressive parkinsonism. Neurobiology of Aging, 2019, 84, 240.e13-240.e22.	1.5	10
98	Bilateral thigh compartment syndromes from extended sitting with forward bending. Journal of Clinical Neuroscience, 2019, 64, 35-37.	0.8	4
99	Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan. Parkinsonism and Related Disorders, 2019, 60, 146-152.	1.1	27
100	A Randomized Crossover Pilot Study of Telemedicine Delivered via iPads in Parkinson's Disease. Parkinson's Disease, 2019, 2019, 1-7.	0.6	26
101	Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's disease. Journal of Neural Transmission, 2019, 126, 289-297.	1.4	8
102	Evaluation of nocturnal hypokinesia in Parkinson's disease using a novel patient/proxy questionnaire and correlations with objective monitoring. Parkinsonism and Related Disorders, 2019, 61, 219-223.	1.1	10
103	Genetic analysis of TMEM230 in Japanese patients with familial Parkinson's disease. Parkinsonism and Related Disorders, 2018, 48, 107-108.	1.1	9
104	Dopamine transporter imaging predicts motor responsiveness to levodopa challenge in patients with Parkinson's disease: A pilot study of DATSCAN for subthalamic deep brain stimulation. Journal of the Neurological Sciences, 2018, 385, 134-139.	0.3	7
105	Neurite orientation dispersion and density imaging of the nigrostriatal pathway in Parkinson's disease: Retrograde degeneration observed by tract-profile analysis. Parkinsonism and Related Disorders, 2018, 51, 55-60.	1.1	47
106	Depressive symptoms in Parkinson's disease are related to decreased left hippocampal volume: correlation with the 15-item shortened version of the Geriatric Depression Scale. Acta Radiologica, 2018, 59, 341-345.	0.5	18
107	Association between abnormal nocturnal blood pressure profile and dementia in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 46, 24-29.	1.1	19
108	Connectome analysis with diffusion MRI in idiopathic Parkinson's disease: Evaluation using multi-shell, multi-tissue, constrained spherical deconvolution. NeuroImage: Clinical, 2018, 17, 518-529.	1.4	51

#	Article	IF	CITATIONS
109	Isolated nigral degeneration without pathological protein aggregation in autopsied brains with LRRK2 p.R1441H homozygous and heterozygous mutations. Acta Neuropathologica Communications, 2018, 6, 105.	2.4	34
110	Bacteria–Host Interactions in Multiple Sclerosis. Frontiers in Microbiology, 2018, 9, 2966.	1.5	36
111	Rapid dissemination of alpha-synuclein seeds through neural circuits in an in-vivo prion-like seeding experiment. Acta Neuropathologica Communications, 2018, 6, 96.	2.4	56
112	Astrocyte-Derived Exosomes Treated With a Semaphorin 3A Inhibitor Enhance Stroke Recovery via Prostaglandin D ₂ Synthase. Stroke, 2018, 49, 2483-2494.	1.0	78
113	<scp>NDP</scp> 52 interacts with mitochondrial <scp>RNA</scp> poly(A) polymerase to promote mitophagy. EMBO Reports, 2018, 19, .	2.0	24
114	Fatal ischemic stroke caused by cerebral small arteritis in a patient with giant cell arteritis. Journal of the Neurological Sciences, 2018, 391, 22-24.	0.3	3
115	Bilateral Caudate Nucleus Infarctions Following Upper Gastrointestinal Bleeding. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, e219-e220.	0.7	3
116	Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease. Movement Disorders, 2018, 33, 1488-1492.	2.2	39
117	GCH1 mutations in dopa-responsive dystonia and Parkinson's disease. Journal of Neurology, 2018, 265, 1860-1870.	1.8	29
118	The Importance of Combined Antithrombotic Treatment for Capsular Warning Syndrome. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 3095-3099.	0.7	7
119	Exploring Bedroom Usability and Accessibility in Parkinson's Disease (PD): The Utility of a PD Home Safety Questionnaire and Implications for Adaptations. Frontiers in Neurology, 2018, 9, 360.	1.1	5
120	Regulation of membrane dynamics by Parkinson's disease-associated genes. Journal of Genetics, 2018, 97, 715-727.	0.4	8
121	Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study. Parkinsonism and Related Disorders, 2018, 53, 21-27.	1.1	21
122	Age Stratification and Impact of Eicosapentaenoic Acid and Docosahexaenoic Acid to Arachidonic Acid Ratios in Ischemic Stroke Patients. Journal of Atherosclerosis and Thrombosis, 2018, 25, 593-605.	0.9	16
123	The presence of cerebral microbleeds is associated with cognitive impairment in Parkinson's disease. Journal of the Neurological Sciences, 2018, 393, 39-44.	0.3	17
124	Alpha-synuclein and familial Parkinson's disease. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY54-1.	0.0	0
125	Istradefylline for Restless Legs Syndrome Associated with Parkinson's Disease. Tremor and Other Hyperkinetic Movements, 2018, 8, 521.	1.1	2
126	Regulation of membrane dynamics by Parkinson's disease-associated genes. Journal of Genetics, 2018, 97, 715-725.	0.4	4

#	Article	IF	CITATIONS
127	Management of impulse control disorders with deep brain stimulation: A double-edged sword. Journal of the Neurological Sciences, 2017, 374, 63-68.	0.3	25
128	<scp>N</scp> europathology of <scp>PARK14</scp> is identical to idiopathic <scp>P</scp> arkinson's disease. Movement Disorders, 2017, 32, 799-800.	2.2	13
129	Neuromelanin MRI is useful for monitoring motor complications in Parkinson's and PARK2 disease. Journal of Neural Transmission, 2017, 124, 407-415.	1.4	31
130	Gray Matter Abnormalities in Idiopathic <scp>P</scp> arkinson's Disease: Evaluation by Diffusional Kurtosis Imaging and Neurite Orientation Dispersion and Density Imaging. Human Brain Mapping, 2017, 38, 3704-3722.	1.9	78
131	Twenty years since the discovery of the parkin gene. Journal of Neural Transmission, 2017, 124, 1037-1054.	1.4	34
132	Management of myasthenia gravis in daily practice for general neurologists and healthcare professionals. Clinical and Experimental Neuroimmunology, 2017, 8, 162-170.	0.5	3
133	Loss of Parkinson's disease-associated protein CHCHD2 affects mitochondrial crista structure and destabilizes cytochrome c. Nature Communications, 2017, 8, 15500.	5.8	123
134	Acute Hearing Loss Caused by Decreasing Anterior Inferior Cerebellar Arterial Perfusion in a Patient with Vertebral Artery Stenosis. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, e119-e121.	0.7	3
135	<i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> in Japanese multiple sclerosis. Clinical and Experimental Neuroimmunology, 2017, 8, 5-6.	0.5	1
136	Subthalamic nucleus and globus pallidus interna influence firing of tonically active neurons in the primate striatum through different mechanisms. European Journal of Neuroscience, 2017, 46, 2662-2673.	1.2	10
137	Reduced TDP-43 Expression Improves Neuronal Activities in a Drosophila Model of Perry Syndrome. EBioMedicine, 2017, 21, 218-227.	2.7	10
138	Parkin mutation may be associated with serious akinesia in a patient with Parkinson's disease. Journal of the Neurological Sciences, 2017, 379, 119-121.	0.3	2
139	Limb-Shaking Transient Ischemic Attack Induced by Middle Cerebral Artery Dissection after Lung Surgery. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, e197-e198.	0.7	4
140	Homozygous alpha-synuclein p.A53V in familial Parkinson's disease. Neurobiology of Aging, 2017, 57, 248.e7-248.e12.	1.5	83
141	Genotype–phenotype correlations of cysteine replacement in CADASIL. Neurobiology of Aging, 2017, 50, 169.e7-169.e14.	1.5	12
142	A novel mutation of CHCHD2 p.R8H in a sporadic case of Parkinson's disease. Parkinsonism and Related Disorders, 2017, 34, 66-68.	1.1	14
143	A novel immunotoxin reveals a new role for CD321 in endothelial cells. PLoS ONE, 2017, 12, e0181502.	1.1	8
144	An Oral A \hat{l}^2 Vaccine Using a Recombinant Adeno-Associated Virus Vector in Aged Monkeys: Reduction in Plaque Amyloid and Increase in A \hat{l}^2 Oligomers. Journal of Alzheimer's Disease, 2016, 54, 1047-1059.	1.2	21

#	Article	IF	CITATIONS
145	Schizophrenia as a prodromal symptom in aÂpatient harboring SNCA duplication. Parkinsonism and Related Disorders, 2016, 25, 108-109.	1.1	12
146	Emerging Risk Factors for Recurrent Vascular Events in Patients With Embolic Stroke of Undetermined Source. Stroke, 2016, 47, 2714-2721.	1.0	22
147	Acute hippocampal and chronic diffuse white matter involvement in severe methanol intoxication. Neurology, 2016, 87, 2382-2383.	1.5	3
148	Tumefactive demyelinating brain lesions with multiple closed-ring enhancement in the course of neuromyelitis optica. Journal of the Neurological Sciences, 2016, 361, 49-51.	0.3	6
149	Movement disorders: advances in 2015. Lancet Neurology, The, 2016, 15, 8-9.	4.9	8
150	Exendin-4 Inhibits Matrix Metalloproteinase-9 Activation and Reduces Infarct Growth After Focal Cerebral Ischemia in Hyperglycemic Mice. Stroke, 2016, 47, 1328-1335.	1.0	45
151	FBXO7 mutations in Parkinson's disease and multiple system atrophy. Neurobiology of Aging, 2016, 40, 192.e1-192.e5.	1.5	43
152	Neurite orientation dispersion and density imaging in the substantia nigra in idiopathic Parkinson disease. European Radiology, 2016, 26, 2567-2577.	2.3	100
153	Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 295-301.	0.9	214
154	The Parkinson's Disease-Associated Protein Kinase LRRK2 Modulates Notch Signaling through the Endosomal Pathway. PLoS Genetics, 2015, 11, e1005503.	1.5	59
155	Sensory tricks for isolated speech-induced lingual dystonia. BMJ Case Reports, 2015, 2015, bcr2014208272-bcr2014208272.	0.2	4
156	TBK1 controls autophagosomal engulfment of polyubiquitinated mitochondria through p62/SQSTM1 phosphorylation. Human Molecular Genetics, 2015, 24, 4429-4442.	1.4	249
157	CHCHD2 and Parkinson's diseaseâ€"Authors' reply. Lancet Neurology, The, 2015, 14, 682-683.	4.9	6
158	Possible involvement of iron-induced oxidative insults in neurodegeneration. Neuroscience Letters, 2015, 588, 29-35.	1.0	13
159	CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study. Lancet Neurology, The, 2015, 14, 274-282.	4.9	285
160	High frequency of beta-propeller protein-associated neurodegeneration (BPAN) among patients with intellectual disability and young-onset parkinsonism. Neurobiology of Aging, 2015, 36, 2004.e9-2004.e15.	1.5	34
161	The twenty-four KDa C-terminal tau fragment increases with aging in tauopathy mice: implications of prion-like properties. Human Molecular Genetics, 2015, 24, 6403-6416.	1.4	50
162	Asian perspectives on the recognition and management of levodopa â€~wearing-off' in Parkinson's disease. Expert Review of Neurotherapeutics, 2015, 15, 1285-1297.	1.4	22

#	Article	IF	Citations
163	What is the evidence to support home environmental adaptation in Parkinson's disease? A call for multidisciplinary interventions. Parkinsonism and Related Disorders, 2015, 21, 1127-1132.	1.1	25
164	Impact of BNP on cryptogenic stroke without potential embolic sources on transesophageal echocardiography. Journal of the Neurological Sciences, 2015, 359, 287-292.	0.3	6
165	Daytime symptoms of restless legs syndrome – clinical characteristics and rotigotine effectiveness. Sleep Medicine, 2015, 16, 871-876.	0.8	9
166	Automatic behavior in Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 84-85.	1.1	2
167	L-Carnitine Enhances Axonal Plasticity and Improves White-Matter Lesions after Chronic Hypoperfusion in Rat Brain. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 382-391.	2.4	59
168	Movement disorders in neoplastic brain disease. , 2014, , 279-292.		1
169	Phosphorylation of Mitochondrial Polyubiquitin by PINK1 Promotes Parkin Mitochondrial Tethering. PLoS Genetics, 2014, 10, e1004861.	1.5	140
170	REST as a new therapeutic target for neurodegenerative disorders. Movement Disorders, 2014, 29, 869-869.	2.2	3
171	Official Japanese Version of the International Parkinson and Movement Disorder Society–Unified Parkinson's Disease Rating Scale: Validation Against the Original English Version. Movement Disorders Clinical Practice, 2014, 1, 200-212.	0.8	47
172	A preliminary diffusional kurtosis imaging study of Parkinson disease: comparison with conventional diffusion tensor imaging. Neuroradiology, 2014, 56, 251-258.	1.1	94
173	The evaluation of polyglutamine repeats in autosomal dominant Parkinson's disease. Neurobiology of Aging, 2014, 35, 1779.e17-1779.e21.	1.5	17
174	PARK2/Parkin-mediated mitochondrial clearance contributes to proteasome activation during slow-twitch muscle atrophy via NFE2L1 nuclear translocation. Autophagy, 2014, 10, 631-641.	4.3	44
175	Singular localization of sodium channel \hat{l}^24 subunit in unmyelinated fibres and its role in the striatum. Nature Communications, 2014, 5, 5525.	5.8	61
176	Juvenile-onset parkinsonism with digenic parkin and PINK1 mutations treated with subthalamic nucleus stimulation at 45years after disease onset. Journal of the Neurological Sciences, 2014, 345, 276-277.	0.3	12
177	Regulation by mitophagy. International Journal of Biochemistry and Cell Biology, 2014, 53, 147-150.	1.2	40
178	Yokukansan Ameliorates Psychiatric Problems in Parkinson's Disease. Juntendo Medical Journal, 2014, 60, 529-535.	0.1	0
179	Relationship between cognitive impairment and white-matter alteration in Parkinson's disease with dementia: tract-based spatial statistics and tract-specific analysis. European Radiology, 2013, 23, 1946-1955.	2.3	80
180	Aging, Aortic Arch Calcification, and Multiple Brain Infarcts Are Associated with Aortogenic Brain Embolism. Cerebrovascular Diseases, 2013, 35, 282-290.	0.8	28

#	Article	IF	Citations
181	Motor and non-motor symptoms of 1453 patients with Parkinson's disease: Prevalence and risks. Parkinsonism and Related Disorders, 2013, 19, 725-731.	1.1	79
182	PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy. Scientific Reports, 2012, 2, 1002.	1.6	466
183	Mitochondrial dysfunction associated with increased oxidative stress and $\hat{l}\pm$ -synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Molecular Brain, 2012, 5, 35.	1.3	333
184	Mechanisms of Genomic Instabilities Underlying Two Common Fragile-Site-Associated Loci, PARK2 and DMD, in Germ Cell and Cancer Cell Lines. American Journal of Human Genetics, 2010, 87, 75-89.	2.6	85
185	p62/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria. Genes To Cells, 2010, 15, 887-900.	0.5	345
186	Tau and neurodegenerative disorders. Biomolecular Concepts, 2010, 1, 131-145.	1.0	4
187	PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. Journal of Cell Biology, 2010, 189, 211-221.	2.3	1,600
188	Four Cases of Tetanus: Its Diagnosis and Management of Complications. Juntendoì,, Igaku, 2010, 56, 68-72.	0.1	1
189	Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease. Journal of Neurochemistry, 2009, 111, 1075-1093.	2.1	93
190	Genomic investigation of αâ€synuclein multiplication and parkinsonism. Annals of Neurology, 2008, 63, 743-750.	2.8	316
191	Animal models of Parkinson's disease: Similarities and differences between the disease and models. Neuropathology, 2007, 27, 479-483.	0.7	20
192	14-3-3η is a novel regulator of parkin ubiquitin ligase. EMBO Journal, 2006, 25, 211-221.	3.5	107
193	Recessive Parkinson's disease. Movement Disorders, 2006, 21, 885-893.	2.2	31
194	Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations. Movement Disorders, 2006, 21, 1384-1395.	2.2	126
195	Decline of striatal dopamine release in parkin-deficient mice shown by ex vivo autoradiography. Journal of Neuroscience Research, 2006, 84, 1350-1357.	1.3	57
196	Clinical heterogeneity of α-synuclein gene duplication in Parkinson's disease. Annals of Neurology, 2006, 59, 298-309.	2.8	308
197	Multiple candidate gene analysis identifies \hat{l} ±-synuclein as a susceptibility gene for sporadic Parkinson's disease. Human Molecular Genetics, 2006, 15, 1151-1158.	1.4	210
198	Diverse Effects of Pathogenic Mutations of Parkin That Catalyze Multiple Monoubiquitylation in Vitro. Journal of Biological Chemistry, 2006, 281, 3204-3209.	1.6	166

#	Article	IF	CITATIONS
199	Preserved myocardial [123 I]metaiodobenzylguanidine uptake in autosomal recessive juvenile parkinsonism: First case report. Movement Disorders, 2005, 20, 634-636.	2.2	41
200	Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2. Movement Disorders, 2005, 20, 1350-1353.	2.2	86
201	A Combinatorial Code for the Interaction of α-Synuclein with Membranes. Journal of Biological Chemistry, 2005, 280, 31664-31672.	1.6	180
202	Common anti-apoptotic roles of parkin and \hat{l}_{\pm} -synuclein in human dopaminergic cells. Biochemical and Biophysical Research Communications, 2005, 332, 233-240.	1.0	74
203	Ubiquitin, proteasome and parkin. Biochimica Et Biophysica Acta - Molecular Cell Research, 2004, 1695, 235-247.	1.9	108
204	Autosomal recessive parkinsonism linked to parkin gene in a Tunisian family. Clinical, genetic and pathological study. Parkinsonism and Related Disorders, 2003, 9, 247-251.	1.1	77
205	Ubiquitination of a New Form of alpha -Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease. Science, 2001, 293, 263-269.	6.0	1,033
206	An Unfolded Putative Transmembrane Polypeptide, which Can Lead to Endoplasmic Reticulum Stress, Is a Substrate of Parkin. Cell, 2001, 105, 891-902.	13.5	1,008
207	Parkin is associated with cellular vesicles. Journal of Neurochemistry, 2001, 78, 42-54.	2.1	119
208	Autosomal recessive juvenile parkinsonism: A key to understanding nigral degeneration in sporadic Parkinson's disease. Neuropathology, 2000, 20, 85-90.	0.7	91
209	Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genetics, 2000, 25, 302-305.	9.4	1,894
210	Polymorphism in theparkin gene in sporadic Parkinson's disease. Annals of Neurology, 1999, 45, 655-658.	2.8	103
211	Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 1998, 392, 605-608.	13.7	4,813
212	Molecular genetic analysis of a novelParkin gene in Japanese families with autosomal recessive juvenile parkinsonism: Evidence for variable homozygous deletions in theParkin gene in affected individuals. Annals of Neurology, 1998, 44, 935-941.	2.8	354
213	Point Mutations (Thr240Arg and Ala311Stop) in theParkinGene. Biochemical and Biophysical Research Communications, 1998, 249, 754-758.	1.0	193
214	A Microdeletion of D6S305 in a Family of Autosomal Recessive Juvenile Parkinsonism (PARK2). Genomics, 1998, 49, 143-146.	1.3	55
215	Clinical Manifestations and Molecular Backgrounds of Parkinson's Disease Regarding Genes Identified From Familial and Population Studies. Frontiers in Neurology, 0, 13, .	1.1	6